Atherosclerosis pathophysiology

Jump to navigation Jump to search

Atherosclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atherosclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Assessment of Cardiovascular Risk

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocadiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

ACC/AHA Guideline Recommendations

Assessment of cardiovascular risk

Secondary prevention

Case Studies

Case #1

Atherosclerosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atherosclerosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atherosclerosis pathophysiology

CDC on Atherosclerosis pathophysiology

Atherosclerosis pathophysiology in the news

Blogs on Atherosclerosis pathophysiology

Directions to Hospitals Treating Atherosclerosis

Risk calculators and risk factors for Atherosclerosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Assistant Editor-in-Chief: Mohammad I. Barouqa, M.D.[2]

Synonyms and keywords: Atherosclerosis, Atherogenesis, Atheroma, Coronary Artery Disease, CAD, Cerebrovascular Disease

Overview

Atherothrombotic diseases are a major healthcare dilemma and contribute to more that 25% of all deaths worldwide.Recent WHO reports indicate that the disease affect developing and developed countries making atherothrombotic diseases a global challenge.[1]

Atherosclerosis is a chronic inflammatory process of the arterial wall which involves an imbalanced lipid metabolism and a maladaptive immune response. The abnormal process of lipid accumulation, immune responses and their clearance is controlled by leukocytes and homeostasis which act in response to chemokines.

Atherogenesis is the developmental process of atheromatous plaques. It is characterized by a remodeling of arteries involving the concomitant accumulation of fatty substances called plaques. One recent theory suggests that for unknown reasons, leukocytes such as monocytes or basophils begin to attack the endothelium of the artery lumen in cardiac muscle. The ensuing inflammation leads to formation of atheromatous plaques in the arterial tunica intima, a region of the vessel wall located between the endothelium and the tunica media and tunica adventitia. The bulk of these lesions are made of excess fat, collagen, and elastin. Initially, as the plaques grow only wall thickening occurs without any narrowing, stenosis of the artery opening, called the lumen; stenosis is a late event which may never occur and is often the result of repeated plaque rupture and healing responses, not the just atherosclerosis process by itself.

Pathophysiology

Pathologically, the atheromatous plaque is divided into three distinct components:

  • The atheroma ("lump of porridge", from Athera, porridge in Greek,) is the nodular accumulation of a soft, flaky, yellowish material at the center of large plaques, composed of macrophages nearest the lumen of the artery.
  • Underlying areas of cholesterol crystals.
  • Calcification at the outer base of older/more advanced lesions.

Cellular

The first phase of atherogenesis is the development of fatty streaks. Histological studies showed that focal thickening of the intima with an increase in smooth muscle cells and extracellular matrix initiate the formation of fatty streaks.[2] These smooth muscle cells,some of which originate from hematopoietic stem cells, migrate and proliferate within the intima.Lipids accumulate early in fatty streaks and lead to the formation of both intracellular and extracellular lipid deposits.Among the lipids deposited is the Biglycan,a small dermatan sulfate proteoglycan,which can trap and bind Apolipoprotein E,VLDL remnants,LDL and HDL.[3]Fatty streaks contain Macrophages and variable amounts of T-Lymphocytes which release a variety of inflammatory mediators.When these Macrophages are filled with fats within fatty streaks,they turn into foam cells.These foam cells are considered to be the hallmark of early atheroma.

As fatty streaks expand, more smooth muscle cells migrate to intima and more lipid deposits will be formed. The smooth muscle cells within the deep layers of fatty streaks undergo apoptosis. Once apoptosis occur, more macrophages migrate along with microvesicles and calcify later on. This process contributes to the transition of fatty streaks into atherosclerotic plagues.[4]

LDL in blood plasma poses a risk for cardiovascular disease when it invades the endothelium and becomes oxidized. A complex set of biochemical reactions regulates the oxidation of LDL, chiefly stimulated by presence of free radicals in the endothelium or blood vessel lining.

The initial damage to the blood vessel wall results in a "call for help," an inflammation response. Monocytes (a type of white blood cell) enter the artery wall from the bloodstream, with platelets adhering to the area of insult. This may be promoted by redox signaling induction of factors such as VCAM-1, which recruit circulating monocytes. The monocytes differentiate into macrophages, which ingest oxidized LDL, slowly turning into large "foam cells" – so-described because of their changed appearance resulting from the numerous internal cytoplasmic vesicles and resulting high lipid content.It is worth to note that the oxidation of LDL is mandatory for their uptake by macrophages via unregulated macrophage sacavenger receptors. Under the microscope, the lesion now appears as a fatty streak.Although the LDL uptake may initially be an adaptive process, which prevents LDL-induced endothelial damage, this sort of accumulation results in mitochondrial dysfunction ,apoptosis and necrosis. Thus,Foam cells eventually die, and further propagate the inflammatory process via the release of proteases, inflammatory cytokines and prothrombotic molecules. There is also smooth muscle proliferation and migration from tunica media to intima responding to cytokines secreted by damaged endothelial cells. This would cause the formation of a fibrous capsule covering the fatty streak.

Calcification and Lipids

Intracellular microcalcifications form within vascular smooth muscle cells of the surrounding muscular layer, specifically in the muscle cells adjacent to the atheromas. In time, as cells die, this leads to extracellular calcium deposits between the muscular wall and outer portion of the atheromatous plaques.

Cholesterol is delivered into the vessel wall by cholesterol-containing low-density lipoprotein (LDL) particles. To attract and stimulate macrophages, the cholesterol must be released from the LDL particles and oxidized, a key step in the ongoing inflammatory process. The process is worsened if there is insufficient high-density lipoprotein (HDL), the lipoprotein particle that removes cholesterol from tissues and carries it back to the liver.

The foam cells and platelets encourage the migration and proliferation of smooth muscle cells, which in turn ingest lipids, become replaced by collagen and transform into foam cells themselves. A protective fibrous cap normally forms between the fatty deposits and the artery lining (the intima).

These capped fatty deposits (now called atheromas) produce enzymes that cause the artery to enlarge over time. As long as the artery enlarges sufficiently to compensate for the extra thickness of the atheroma, then no narrowing, stenosis, of the opening, lumen, occurs. The artery becomes expanded with an egg-shaped cross-section, still with a circular opening. If the enlargement is beyond proportion to the atheroma thickness, then an aneurysm is created.[5]

Visible Features

Although arteries are not typically studied microscopically, two plaque types can be distinguished[3]:

  • The fibro-lipid (fibro-fatty) plaque is characterized by an accumulation of lipid-laden cells underneath the intima of the arteries, typically without narrowing the lumen due to compensatory expansion of the bounding muscular layer of the artery wall. Beneath the endothelium there is a "fibrous cap" covering the atheromatous "core" of the plaque. The core consists of lipid-laden cells (macrophages and smooth muscle cells) with elevated tissue cholesterol and cholesterol ester content, fibrin, proteoglycans, collagen, elastin and cellular debris. In advanced plaques, the central core of the plaque usually contains extracellular cholesterol deposits (released from dead cells), which form areas of cholesterol crystals with empty, needle-like clefts. At the periphery of the plaque are younger "foamy" cells and capillaries. These plaques usually produce the most damage to the individual when they rupture.
  • The fibrous plaque is also localized under the intima, within the wall of the artery resulting in thickening and expansion of the wall and, sometimes, spotty localized narrowing of the lumen with some atrophy of the muscular layer. The fibrous plaque contains collagen fibres (eosinophilic), precipitates of calcium (hematoxylinophilic) and, rarely, lipid-laden cells.

In effect, the muscular portion of the artery wall forms small aneurysms just large enough to hold the atheroma that are present. The muscular portion of artery walls usually remain strong, even after they have remodeled to compensate for the atheromatous plaques.

However, atheromas within the vessel wall are soft and fragile with little elasticity. Arteries constantly expand and contract with each heartbeat, i.e., the pulse. In addition, the calcification deposits between the outer portion of the atheroma and the muscular wall, as they progress, lead to a loss of elasticity and stiffening of the artery as a whole.

The calcification deposits, after they have become sufficiently advanced, are partially visible on coronary artery computed tomography or electron beam tomography (EBT) as rings of increased radiographic density, forming halos around the outer edges of the atheromatous plaques, within the artery wall. On CT, >130 units on the Hounsfield scale (some argue for 90 units) has been the radiographic density usually accepted as clearly representing tissue calcification within arteries. These deposits demonstrate unequivocal evidence of the disease, relatively advanced, even though the lumen of the artery is often still normal by angiographic or intravascular ultrasound.

Rupture and Stenosis

Although the disease process tends to be slowly progressive over decades, it usually remains asymptomatic until an atheroma obstructs the bloodstream in the artery. This is typically by rupture of an atheroma, clotting and fibrous organization of the clot within the lumen, covering the rupture but also producing stenosis, or over time and after repeated ruptures, resulting in a persistent, usually localized stenosis. Stenoses can be slowly progressive, while plaque rupture is a sudden event that occurs specifically in atheromas with thinner/weaker fibrous caps that have become "unstable".

Repeated plaque ruptures, ones not resulting in total lumen closure, combined with the clot patch over the rupture and healing response to stabilize the clot, is the process that produces most stenoses over time. The stenotic areas tend to become more stable, despite increased flow velocities at these narrowings. Most major blood-flow-stopping events occur at large plaques, which, prior to their rupture, produced very little if any stenosis.

From clinical trials, 20% is the average stenosis at plaques that subsequently rupture with resulting complete artery closure. Most severe clinical events do not occur at plaques that produce high-grade stenosis. From clinical trials, only 14% of heart attacks occur from artery closure at plaques producing a 75% or greater stenosis prior to the vessel closing.

If the fibrous cap separating a soft atheroma from the bloodstream within the artery ruptures, tissue fragments are exposed and released, and blood enters the atheroma within the wall and sometimes results in a sudden expansion of the atheroma size. Tissue fragments are very clot-promoting, containing collagen and tissue factor; they activate platelets and activate the system of coagulation. The result is the formation of a thrombus (blood clot) overlying the atheroma, which obstructs blood flow acutely. With the obstruction of blood flow, downstream tissues are starved of oxygen and nutrients. If this is the myocardium (heart muscle), angina (cardiac chest pain) or myocardial infarction (heart attack) develops.

Rather than a single plaque rupture, atherosclerosis is the result of multiple plaque ruptures over time. In patients with ACS, autopsy data show that there had been 5-7 ruptures before the terminal event. These events often due to not lead to a coronary event. Thin capped fibroatheroma (TCFA) with rupture is the most common form of plaque rupture. A less common form is erosion of the plaque. Intraplaque hemorrhage as a result of rupture of the vasa vasorum may also occur. Most ACS is due to TCFA plaque rupture. Less likely there is plaque erosion in ACS. Younger women more often have plaque erosion. Older women more often have plaque rupture. Plaque rupture is usually the mechanism in young men. In older men, the mechanism is similar to women. You cannot predict what plaque is going to rupture on the angiogram. Virtual histology and OCT may potentially predict plaque rupture, but the odds of rupture are so low that their utility is marginal.

Pathological Findings

Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology







Saphenous Vein Graft


Coronary Arteries

Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology




Aorta

Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

Carotid Artery

Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

Lung

Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

Pulmonary Artery

Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

Brain

Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

Kidney

Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

References

  1. Weber, C.; Noels, H. (2011). "Atherosclerosis: current pathogenesis and therapeutic options". Nat Med. 17 (11): 1410–22. doi:10.1038/nm.2538. PMID 22064431.
  2. Davies, MJ.; Woolf, N.; Rowles, PM.; Pepper, J. (1988). "Morphology of the endothelium over atherosclerotic plaques in human coronary arteries". Br Heart J. 60 (6): 459–64. PMID 3066389. Unknown parameter |month= ignored (help)
  3. O'Brien, KD.; Olin, KL.; Alpers, CE.; Chiu, W.; Ferguson, M.; Hudkins, K.; Wight, TN.; Chait, A. (1998). "Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins". Circulation. 98 (6): 519–27. PMID 9714108. Unknown parameter |month= ignored (help)
  4. Kockx, MM.; De Meyer, GR.; Muhring, J.; Jacob, W.; Bult, H.; Herman, AG. (1998). "Apoptosis and related proteins in different stages of human atherosclerotic plaques". Circulation. 97 (23): 2307–15. PMID 9639374. Unknown parameter |month= ignored (help)
  5. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:131-1375. PMID

Template:WH Template:WS